Price alert —
Sign in to get a one-time email the moment NOVN.SW crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · NOVN.SW
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $13.5B | $3.2B | $4.2B | $2.9B | 23.3% | 31.3% |
| 2025-12-31 | $13.9B | $2.4B | $3.6B | $1.2B | 17.4% | 26.1% |
| 2025-09-30 | $14.4B | $3.9B | $4.5B | $5.7B | 27.4% | 31.3% |
| 2025-06-30 | $14.8B | $4.0B | $4.9B | $6.1B | 27.2% | 32.8% |
| 2025-03-31 | $13.6B | $3.6B | $4.7B | $2.2B | 26.5% | 34.2% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare NOVN.SW vs peers
Line NOVN.SW up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with NOVN.SW
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-07-20 | 2.41 | 2.14 | +12.7% | +2.0% |
| 2026-04-27 | 1.99 | 2.08 | -4.5% | +0.6% |
| 2026-02-04 | 2.03 | 2.07 | -1.7% | +0.5% |
| 2025-10-28 | 2.04 | 1.87 | +9.0% | -0.4% |
| 2025-07-17 | 2.42 | 2.37 | +2.0% | -1.1% |
| 2025-04-29 | 2.28 | 2.15 | +6.3% | -0.5% |
| 2025-01-30 | 1.98 | 1.82 | +8.7% | +1.9% |
| 2024-10-28 | 2.06 | 1.94 | +5.9% | -4.1% |
| 2024-07-17 | 1.97 | 1.87 | +5.5% | -4.0% |
| 2024-04-23 | 1.80 | 1.68 | +7.0% | +0.2% |
| 2024-01-31 | 1.53 | 1.61 | -5.2% | +1.3% |
| 2023-10-23 | 1.74 | 1.68 | +3.3% | +0.7% |
| 2023-07-17 | 1.83 | 1.70 | +7.4% | +4.6% |
| 2023-04-25 | 1.71 | 1.54 | +11.3% | -1.6% |
| 2023-01-31 | 1.52 | 1.41 | +7.4% | -2.7% |
| 2022-10-25 | 1.58 | 1.54 | +2.3% | +1.0% |
| 2022-07-19 | 1.56 | 1.49 | +4.5% | -1.2% |
| 2022-04-26 | 1.46 | 1.45 | +0.6% | +0.7% |
| 2022-02-02 | 1.40 | 1.42 | -1.6% | +1.1% |
| 2021-10-26 | 1.71 | 1.64 | +4.2% | -2.4% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| NOVN.SW ★ | $238B | 22.2 | 16.0 | 4.2 | 12.6 | 7.7 | 74.9% | 0.8% | -17.0% | 3.59% |
| LLY | $1,040B | 41.5 | 26.0 | — | 30.0 | 33.4 | 82.8% | 55.5% | 169.9% | 0.88% |
| UNH | $393B | 32.6 | 19.3 | 0.9 | 18.1 | 3.8 | 19.5% | 0.4% | 61.5% | 5.79% |
| JNJ | $615B | 29.7 | 19.9 | 6.3 | 18.3 | 7.6 | 68.1% | 6.6% | -1.0% | — |
| MRK | $316B | 36.0 | 13.3 | — | 12.0 | 6.9 | 76.7% | 4.9% | — | 4.45% |
| ABBV | $452B | 124.7 | 15.7 | 7.2 | 17.2 | -67.9 | 72.0% | 12.4% | -46.2% | 4.61% |
| PFE | $142B | 19.1 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.69% |
| TMO | $194B | 28.7 | 19.2 | — | 20.8 | 3.7 | 40.9% | 6.2% | 11.3% | 2.85% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 0.02%
| Holder | Shares | % out |
|---|---|---|
| Pacer Advisors, Inc. | 457,072 | 0.02% |
| Partners Capital Investment Group, L | 28,214 | — |
| Paradigm Asset Management Company, L | 21,514 | — |
| Generali Investments Cee, Investicni | 15,729 | — |
Insider activity · 90d
No insider trades for NOVN.SW in last 90d.
Analyst estimates
yfinanceWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
Consensus: hold (mean 2.63636). Distribution requires FINNHUB_API_KEY.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
No CIK found for NOVN.SW.
About NOVN.SW
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespeci…
Options picks · NOVN.SW
ITM + OTM ideas from the latest scanLoading…
Congress trades · NOVN.SW
STOCK Act disclosuresLoading…
SEC filings & insiders · NOVN.SW
EDGAR · liveLoading…
Holders · NOVN.SW
Institutions & insider activityLoading…